Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

BioStorage Launches INTEGRITY Study

Published: Thursday, August 22, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
Measures effect of time, temperature and preparation methods on DNA and RNA samples.

BioStorage Technologies has announced that the company has initiated the INTEGRITY Study. The 24-month study will analyze human whole blood samples to measure the impact on the long-term integrity of DNA and RNA when various preparation methods, storage temperatures and storage times are applied.

Conducted at BioStorage Technologies’ global biorepository in Indianapolis, the study will compare fresh samples, frozen pre-extracted samples and extracted nucleic acids, which require freeze/ thaw cycles for processing.

Various storage temperatures and aliquoting strategies will be evaluated and reported over the length of the study.

“The INTEGRITY study has a unique comprehensive study design that will help provide the industry with recommended best practices and techniques to support the optimal preservation of DNA and RNA samples for prospective and retrospective research studies,” said Lori Ball, COO, BioStorage Technologies.

Ball continued, “Our goal is to determine the effects of various preparation methods on whole blood samples for nucleic acid extraction and the optimal length of time and best temperature to store samples for future research.”

Existing research suggests that inexact sample preparation and storage methods may affect the results or analysis of biological studies and can lead to sample loss, reprocessing or complicated data interpretation.

However, to date, most studies have been designed to analyze the impact of a single temperature and have not been focused on the long-term effects of various temperatures, methods of freeze-thaw and storage time on DNA and RNA integrity within a single study.

“As an advocate for advancing the global biobanking industry, BioStorage Technologies has become an informational resource for best practices at all stages of the sample management life-cycle, and with the INTEGRITY Study we hope to provide data-driven research in a comprehensive single-study format that has never before been done,” said Greg Swanberg, CEO, Biostorage Technologies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioProcessing Solutions Alliance Wins Million Veteran Program Genotyping Contract
The U.S. Department of Veterans Affairs awarded a five-year contract for genotyping to the BioProcessing Solutions Alliance.
Friday, November 08, 2013
Biostorage Technologies Announces Growth into China
Partners with Charles River Labs to expand sample management in the region.
Thursday, October 17, 2013
BioStorage Technologies Adding New Service in Germany
BioStorage Technologies announces the expansion of its temperature-controlled storage options to include vapor-phase liquid nitrogen preservation at its state-of-the-art biorepository facility in Griesheim, Germany.
Wednesday, October 17, 2012
BioStorage Expands its Service Offering to Include Advanced Bioprocessing Solutions
Company has developed a strategic and innovative alliance with RUCDR Infinite Biologics.
Wednesday, August 22, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos